These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12824020)

  • 1. Heterocyclic thrombin inhibitors. Part 1: design and synthesis of amidino-phenoxy quinoline derivatives.
    Ries UJ; Priepke HW; Hauel NH; Haaksma EE; Stassen JM; Wienen W; Nar H
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2291-5. PubMed ID: 12824020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents.
    Ries UJ; Priepke HW; Hauel NH; Handschuh S; Mihm G; Stassen JM; Wienen W; Nar H
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2297-302. PubMed ID: 12824021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amidinohydrazones as guanidine bioisosteres: application to a new class of potent, selective and orally bioavailable, non-amide-based small-molecule thrombin inhibitors.
    Soll RM; Lu T; Tomczuk B; Illig CR; Fedde C; Eisennagel S; Bone R; Murphy L; Spurlino J; Salemme FR
    Bioorg Med Chem Lett; 2000 Jan; 10(1):1-4. PubMed ID: 10636229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.
    Dudley DA; Bunker AM; Chi L; Cody WL; Holland DR; Ignasiak DP; Janiczek-Dolphin N; McClanahan TB; Mertz TE; Narasimhan LS; Rapundalo ST; Trautschold JA; Van Huis CA; Edmunds JJ
    J Med Chem; 2000 Nov; 43(22):4063-70. PubMed ID: 11063603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
    Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
    J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.
    Bachand B; Tarazi M; St-Denis Y; Edmunds JJ; Winocour PD; Leblond L; Siddiqui MA
    Bioorg Med Chem Lett; 2001 Feb; 11(3):287-90. PubMed ID: 11212093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors.
    Dominguez C; Duffy DE; Han Q; Alexander RS; Galemmo RA; Park JM; Wong PC; Amparo EC; Knabb RM; Luettgen J; Wexler RR
    Bioorg Med Chem Lett; 1999 Apr; 9(7):925-30. PubMed ID: 10230612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of isosteres of p-amidinophenylpyruvic acid. Inhibitors of trypsin thrombin, and pancreatic kallikrein.
    Geratz JD; Mar EC; Loeffler LJ; Fox LB
    J Med Chem; 1975 Mar; 18(3):287-92. PubMed ID: 1133820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Synthetic inhibitors of serine proteinases. Part 25: Inhibition of trypsin, plasmin and thrombin by amides of N alpha-substituted amidinophenylalanines and 3-amidinophenyl-3-aminopropionic acids (author's transl)].
    Stürzebecher J; Horn H; Markwardt F; Wagner G; Walsmann P
    Pharmazie; 1981 Sep; 36(9):639-41. PubMed ID: 6458047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
    Lee K; Park CW; Jung WH; Park HD; Lee SH; Chung KH; Park SK; Kwon OH; Kang M; Park DH; Lee SK; Kim EE; Yoon SK; Kim A
    J Med Chem; 2003 Aug; 46(17):3612-22. PubMed ID: 12904065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
    Quan ML; Ellis CD; Liauw AY; Alexander RS; Knabb RM; Lam G; Wright MR; Wong PC; Wexler RR
    J Med Chem; 1999 Jul; 42(15):2760-73. PubMed ID: 10425087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and molecular modelling of 1-amidinopiperidine thrombin inhibitors.
    Smolnikar I; Perdih A; Stegnar M; Prezelj A; Solmajer T; Urleb U; Obreza A
    Pharmazie; 2007 Apr; 62(4):243-54. PubMed ID: 17484277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New aromatic diamidines with central alpha-oxyalkane or alpha, omega-dioxyalkane chains. Structure-activity relationships for the inhibition of trypsin, pancreatic kallikrein, and thrombin and for the inhibition of the overall coagulation process.
    Geratz JD; Cheng MC; Tidwell RR
    J Med Chem; 1975 May; 18(5):477-81. PubMed ID: 1171238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.
    Arnaiz DO; Zhao Z; Liang A; Trinh L; Witlow M; Koovakkat SK; Shaw KJ
    Bioorg Med Chem Lett; 2000 May; 10(9):957-61. PubMed ID: 10853668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin.
    Tidwell RR; Geratz JD; Dubovi EJ
    J Med Chem; 1983 Feb; 26(2):294-8. PubMed ID: 6219223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibition of thrombin, plasmin and trypsin effect by alkyl- and alkoxybenzamidine].
    Markwardt F; Walsmann P; Landmann H
    Pharmazie; 1970 Sep; 25(9):551-4. PubMed ID: 4249689
    [No Abstract]   [Full Text] [Related]  

  • 17. [Synthetic inhibitors of serine proteinases. 5. The inhibition of trypsin, plasmin and thrombin caused by aliphatic amidino compounds having ether structure as well as esters of the 3- and 4-amidinophenoxyfacetic acid].
    Walsmann P; Horn H; Landmann H; Markwardt F; Stürzebecher J; Wagner G
    Pharmazie; 1975 Jun; 30(6):386-9. PubMed ID: 125879
    [No Abstract]   [Full Text] [Related]  

  • 18. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.
    Wiley MR; Weir LC; Briggs S; Bryan NA; Buben J; Campbell C; Chirgadze NY; Conrad RC; Craft TJ; Ficorilli JV; Franciskovich JB; Froelich LL; Gifford-Moore DS; Goodson T; Herron DK; Klimkowski VJ; Kurz KD; Kyle JA; Masters JJ; Ratz AM; Milot G; Shuman RT; Smith T; Smith GF; Tebbe AL; Tinsley JM
    J Med Chem; 2000 Mar; 43(5):883-99. PubMed ID: 10715155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
    South MS; Case BL; Wood RS; Jones DE; Hayes MJ; Girard TJ; Lachance RM; Nicholson NS; Clare M; Stevens AM; Stegeman RA; Stallings WC; Kurumbail RG; Parlow JJ
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2319-25. PubMed ID: 12824026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Synthetic inhibitors of serine proteinases. Part 26: Inhibition of trypsin, plasmin and thrombin by amides of N alpha-arylsulfonylated 2-amino-4-(4-amidino-phenyl) butyric acid and 2-amino-5-amidinophenyl valeric acids (author's transl)].
    Stürzebecher J; Markwardt F; Vieweg H; Wagner G; Walsmann P
    Pharmazie; 1982 Apr; 37(4):281-3. PubMed ID: 6212947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.